173 related articles for article (PubMed ID: 26048680)
1. Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.
Tanizaki J; Ercan D; Capelletti M; Dodge M; Xu C; Bahcall M; Tricker EM; Butaney M; Calles A; Sholl LM; Hammerman PS; Oxnard GR; Wong KK; Jänne PA
Cancer Res; 2015 Aug; 75(15):3139-46. PubMed ID: 26048680
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
Liao RG; Jung J; Tchaicha J; Wilkerson MD; Sivachenko A; Beauchamp EM; Liu Q; Pugh TJ; Pedamallu CS; Hayes DN; Gray NS; Getz G; Wong KK; Haddad RI; Meyerson M; Hammerman PS
Cancer Res; 2013 Aug; 73(16):5195-205. PubMed ID: 23786770
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
4. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC.
Tchaicha JH; Akbay EA; Altabef A; Mikse OR; Kikuchi E; Rhee K; Liao RG; Bronson RT; Sholl LM; Meyerson M; Hammerman PS; Wong KK
Cancer Res; 2014 Sep; 74(17):4676-84. PubMed ID: 25035393
[TBL] [Abstract][Full Text] [Related]
5. Drug-sensitive FGFR2 mutations in endometrial carcinoma.
Dutt A; Salvesen HB; Chen TH; Ramos AH; Onofrio RC; Hatton C; Nicoletti R; Winckler W; Grewal R; Hanna M; Wyhs N; Ziaugra L; Richter DJ; Trovik J; Engelsen IB; Stefansson IM; Fennell T; Cibulskis K; Zody MC; Akslen LA; Gabriel S; Wong KK; Sellers WR; Meyerson M; Greulich H
Proc Natl Acad Sci U S A; 2008 Jun; 105(25):8713-7. PubMed ID: 18552176
[TBL] [Abstract][Full Text] [Related]
6. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
Katoh Y; Katoh M
Int J Mol Med; 2009 Mar; 23(3):307-11. PubMed ID: 19212647
[TBL] [Abstract][Full Text] [Related]
7. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
Bai A; Meetze K; Vo NY; Kollipara S; Mazsa EK; Winston WM; Weiler S; Poling LL; Chen T; Ismail NS; Jiang J; Lerner L; Gyuris J; Weng Z
Cancer Res; 2010 Oct; 70(19):7630-9. PubMed ID: 20709759
[TBL] [Abstract][Full Text] [Related]
8. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N
Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923
[TBL] [Abstract][Full Text] [Related]
9. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.
Krook MA; Barker H; Chen HZ; Reeser JW; Wing MR; Martin D; Smith AM; Dao T; Bonneville R; Samorodnitsky E; Miya J; Freud AG; Monk JP; Clinton SK; Roychowdhury S
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):624-632. PubMed ID: 31043681
[TBL] [Abstract][Full Text] [Related]
11. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.
Salm F; Cwiek P; Ghosal A; Lucia Buccarello A; Largey F; Wotzkow C; Höland K; Styp-Rekowska B; Djonov V; Zlobec I; Bodmer N; Gross N; Westermann F; Schäfer SC; Arcaro A
Oncogene; 2013 Aug; 32(34):3944-53. PubMed ID: 23027129
[TBL] [Abstract][Full Text] [Related]
12.
Cleary JM; Raghavan S; Wu Q; Li YY; Spurr LF; Gupta HV; Rubinson DA; Fetter IJ; Hornick JL; Nowak JA; Siravegna G; Goyal L; Shi L; Brais LK; Loftus M; Shinagare AB; Abrams TA; Clancy TE; Wang J; Patel AK; Brichory F; Vaslin Chessex A; Sullivan RJ; Keller RB; Denning S; Hill ER; Shapiro GI; Pokorska-Bocci A; Zanna C; Ng K; Schrag D; Jänne PA; Hahn WC; Cherniack AD; Corcoran RB; Meyerson M; Daina A; Zoete V; Bardeesy N; Wolpin BM
Cancer Discov; 2021 Oct; 11(10):2488-2505. PubMed ID: 33926920
[TBL] [Abstract][Full Text] [Related]
13. Virtual screening on an α-helix to β-strand switchable region of the FGFR2 extracellular domain revealed positive and negative modulators.
Diaz C; Corentin H; Thierry V; Chantal A; Tanguy B; David S; Jean-Marc H; Pascual F; Françoise B; Edgardo F
Proteins; 2014 Nov; 82(11):2982-97. PubMed ID: 25082719
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of a novel FGFR2 mutation, E731K, in craniosynostosis.
Park J; Park OJ; Yoon WJ; Kim HJ; Choi KY; Cho TJ; Ryoo HM
J Cell Biochem; 2012 Feb; 113(2):457-64. PubMed ID: 21928350
[TBL] [Abstract][Full Text] [Related]
15. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D; Bhin J; Yemelyanenko J; Kas SM; Rolfs F; Lutz C; Lee JK; Klarenbeek S; Silverman IM; Annunziato S; Chan CS; Piersma SR; Eijkman T; Badoux M; Gogola E; Siteur B; Sprengers J; de Klein B; de Goeij-de Haas RR; Riedlinger GM; Ke H; Madison R; Drenth AP; van der Burg E; Schut E; Henneman L; van Miltenburg MH; Proost N; Zhen H; Wientjens E; de Bruijn R; de Ruiter JR; Boon U; de Korte-Grimmerink R; van Gerwen B; Féliz L; Abou-Alfa GK; Ross JS; van de Ven M; Rottenberg S; Cuppen E; Chessex AV; Ali SM; Burn TC; Jimenez CR; Ganesan S; Wessels LFA; Jonkers J
Nature; 2022 Aug; 608(7923):609-617. PubMed ID: 35948633
[TBL] [Abstract][Full Text] [Related]
16. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
17. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis.
Shukla V; Coumoul X; Wang RH; Kim HS; Deng CX
Nat Genet; 2007 Sep; 39(9):1145-50. PubMed ID: 17694057
[TBL] [Abstract][Full Text] [Related]
18. Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells.
Moffa AB; Ethier SP
J Cell Physiol; 2007 Mar; 210(3):720-31. PubMed ID: 17133345
[TBL] [Abstract][Full Text] [Related]
19. The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects.
Ota S; Zhou ZQ; Link JM; Hurlin PJ
Hum Mol Genet; 2009 Jul; 18(14):2609-21. PubMed ID: 19403560
[TBL] [Abstract][Full Text] [Related]
20. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]